Luukkonen TM, Kiiski V, Ahola M, et al. The Value of FLG Null Mutations in Predicting Treatment Response in Atopic Dermatitis: An Observational Study in Finnish Patients. Acta Derm Venereol. 2017;97(4):456-463. doi:10.2340/00015555-2578
Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017;60(9):1648-1655. doi:10.1007/s00125-017-4335-y
Warren CR, Cowan CA. Humanity in a Dish: Population Genetics with iPSCs. Trends Cell Biol. 2018;28(1):46-57. doi:10.1016/j.tcb.2017.09.006
Habeb AM, Flanagan SE, Zulali MA, et al. Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome. Diabetologia. 2018;61(5):1027-1036. doi:10.1007/s00125-018-4554-x
Agostini M, Schoenmakers E, Beig J, et al. A Pharmacogenetic Approach to the Treatment of Patients With Mutations. Diabetes. 2018;67(6):1086-1092. doi:10.2337/db17-1236
Luo B, Cheung HW, Subramanian A, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008;105(51):20380-5. doi:10.1073/pnas.0810485105
Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13(13):1353-9. doi:10.1093/hmg/ddh149
Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7. doi:10.1038/nature11003
Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581-94. doi:10.1038/nrd4051
Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014;63(8):2590-9. doi:10.2337/db13-1367